Biobank for skin cancer collecting blood, tissue, and clinical data
Official title: Prospective Collection of Clinical Data and Human Body Material (HBM): Blood (Serum, Plasma, DNA) and Tissue of Cutaneous Melanoma, Non Melanoma Patients and Healthy Controls. Biobank Huidkanker
Run by Universitaire Ziekenhuizen KU Leuven · NCT07266142 · Data updated 2026-11-12
This project will collect blood, tissue, and clinical information from adults with melanoma or non‑melanoma skin cancer to build a biobank for future research.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 7500 (estimated) |
| Sponsor | Universitaire Ziekenhuizen KU Leuven Academic / other |
| Locations | 1 site (Leuven, Vlaams-Brabant) |
| Status | Recruiting |
| Started | November 17, 2025 |
| Main results expected | January 2050 |
| Study ends | January 2051 |
| Registry record updated | June 12, 2026 |
| Trial ID | NCT07266142 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (age ≥18) diagnosed with cutaneous melanoma or non‑melanoma skin cancer who can provide written informed consent and are willing to provide biological samples and clinical information.
✕Probably not a fit
Patients should not expect direct therapeutic benefit or immediate changes to their treatment from participation, since this protocol is for sample and data collection only.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a prospective collection that gathers standardized clinical data, questionnaire responses, and human body material (blood: serum, plasma, DNA; and tissue) from adults diagnosed with cutaneous melanoma or non‑melanoma skin cancer. Participants provide informed consent, share medical and surgical history and risk factors, complete the Cancer Worry Scale, and give blood and residual or additional tissue samples when consented. Samples and linked clinical data are stored in a biobank under an umbrella protocol and may be used for future approved research via satellite protocols. The protocol does not assign treatments and is designed to support downstream biomarker and translational studies.
Why it matters
Potential benefit: If successful, the biobank could accelerate research that leads to better diagnostics, biomarkers, and eventual improvements in personalized care for skin cancer patients.
How similar studies have gone: Cancer biobanks are an established approach and have previously enabled biomarker discoveries and translational research, so this protocol follows a well‑validated model.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures * Adult subjects (\>18 years of age) at time of enrolment. * Subjects diagnosed with cutaneous melanoma, Non-melanoma skin cancer or healthy controls. * Adult subjects able and willing to provide informed consent. Exclusion Criteria: * Subjects unable or not willing to provide informed consent. * Pregnancy (or willing to become pregnant) is NOT an exclusion criteria (unless specified in the respective satellite protocols.
Where it's running
-
UZLeuven, Department of Dermatology
Leuven, Vlaams-Brabant, Belgium Recruiting
Study contacts
- Study coordinator: Annemiek Leeman, Prof. Dr.
- Email: annemiek.leeman@uzleuven.be
- Phone: 0032 016337950
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
AI-powered early detection of skin cancer using a smartphone
This project tests whether the NuvanaDx smartphone app can detect skin cancer, including melanoma, in adults who have suspicious skin lesions.
-
Impact of hypofractionated radiotherapy after surgery for skin cancer in older patients
This study is testing if a special type of radiation therapy after surgery can help older patients with skin cancer feel better and live healthier lives compared to just having surgery alone.
-
PD-L1-targeted PET probe to map PD-L1 in solid tumors
A PET tracer called 18F-F-PDL1-3 is being tested to see if it can detect PD-L1 expression in primary and metastatic tumors to help guide personalized treatment.
-
ctDNA-guided stopping of immune therapy in advanced melanoma
This study tests whether stopping immune checkpoint inhibitor therapy after 12 months is safe for patients with advanced melanoma who have undetectable ctDNA and disease control.
-
ENPP1/cGAS and FAP in Solid Tumors in Vietnamese Patients
This Vietnam-based study will test ENPP1, cGAS, and FAP expression in archived tumor samples from Vietnamese adults with solid cancers using immunohistochemistry.
-
68Ga-SorB PET/CT imaging for solid tumors
This study tests a new PET tracer called 68Ga-SorB to see if it can safely and accurately detect tumors in adults with melanoma, liver, lung, breast, pancreatic, ovarian cancer, or cholangiocarcinoma.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.